Understanding the Neuroendocrine Prostate Cancer Spectrum: Diagnosis, Treatment, and Future Perspectives

Understanding the Neuroendocrine Prostate Cancer Spectrum: Diagnosis, Treatment, and Future Perspectives

Introduction:
The term "neuroendocrine prostate cancer" has gained significant attention in the field of pathology, particularly in relation to pleomorphic cytology and therapy-related small cell prostate cancer. However, there has been a concern that using the term "therapy-related" introduces bias and may discourage clinicians from exploring potentially positive treatment options. Additionally, the use of "neuroendocrine" has been associated with a poor clinical course, reminiscent of the small cell variant. In this article, we will delve deeper into the diagnosis, treatment, and future perspectives of the neuroendocrine prostate cancer spectrum.

Diagnosis and Clinical Criteria:
At the APCCC 2017 conference, the first-line treatment for aggressive variant prostate cancer was primarily based on clinical criteria. However, this approach resulted in only 42% of participants recommending platinum-based chemotherapy, while the majority suggested standard mCRPC treatment. To refine the diagnosis of aggressive variant prostate cancer, several clinicopathologic criteria have been identified. These include small cell prostate carcinoma, visceral metastases only, lytic bone metastases, bulky nodes or prostate mass, low PSA relative to the volume of disease, elevated neuroendocrine markers and serum CEA or LDH, and primary castration-resistance.

Treatment Approaches:
Dr. Efstathiou's research has shown promising results in the treatment of aggressive variant prostate cancer. Combining carboplatin with cabazitaxel has demonstrated improved median progression-free survival (PFS) compared to cabazitaxel alone. This finding highlights the potential benefits of incorporating platinum-based chemotherapy in the treatment regimen for at-risk men. Furthermore, the serum CEA concentration has been identified as a strong predictor of overall survival (OS) in these patients.

Future Perspectives:
While the term "AR negative prostate cancer" has been commonly used, Dr. Efstathiou believes it is too limiting. Instead, he suggests using the term "androgen indifferent prostate cancer" to encompass tumors that may still respond to novel androgen signaling inhibition. It is crucial not to introduce bias and withhold potentially effective hormonal therapies based solely on terminology. Another term, "therapy-related neuroendocrine prostate cancer," offers a more accurate description but raises concerns about clinicians withholding hormonal therapies. As the field progresses, it is essential to find a less confusing yet comprehensive definition for aggressive variants of prostate cancer.

Actionable Advice:

1. Emphasize Comprehensive Diagnostic Criteria: Clinicians should consider a range of clinicopathologic criteria when diagnosing aggressive variant prostate cancer, including neuroendocrine markers, serum CEA or LDH levels, and primary castration-resistance. This comprehensive approach will help identify patients who may benefit from more aggressive treatment strategies.

2. Incorporate Platinum-based Chemotherapy: The combination of carboplatin and cabazitaxel has shown promising results in improving progression-free survival. Clinicians should consider incorporating platinum-based chemotherapy in the treatment regimen for at-risk men with aggressive variant prostate cancer.

3. Avoid Bias in Treatment Decision-making: It is crucial to avoid introducing bias when determining the most suitable treatment approach for patients with aggressive variant prostate cancer. Clinicians should base their decisions on a comprehensive assessment of the patient's clinical criteria, response to hormonal therapies, and potential benefits of novel treatment options.

Conclusion:
The neuroendocrine prostate cancer spectrum presents unique challenges in diagnosis and treatment. By understanding the clinicopathologic criteria, incorporating platinum-based chemotherapy, and avoiding biased decision-making, clinicians can provide more effective management strategies for patients. As research continues to uncover new insights into this complex disease, it is crucial to refine our understanding of the terminology and develop more accurate definitions for aggressive variants of prostate cancer.